AVODART(Dutasteride) Post-marketing Surveillance(PMS)

• Status: Completed
• Trial end date: 2010-07-01
• Target enrollment: 0
• Participant gender: Male

Summary

An open label, multi-centre, non-interventional post-marketing surveillance to monitor the safety and/or efficacy of AVODART administered in Korean BPH patients according to the prescribing information

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: GlaxoSmithKline
• Treatments: Dutasteride

Criteria

Inclusion Criteria:

• The Korean BPH Patients administrated dutasteride according to the prescribing information

Exclusion Criteria:

• women and children and adolescents.

• patients with hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any of the excipients.